Adjuvant Chemotherapy Use for Hormone Receptor-Positive, ERBB2-Negative Breast Cancer After RxPONDER Trial.

Adjuvant Chemotherapy Use for Hormone Receptor-Positive, ERBB2-Negative Breast Cancer After RxPONDER Trial. JAMA Netw Open. 2025 Dec 01; 8(12):e2549109.

View in: PubMed

subject areas

Adult
Aged
Breast Neoplasms
Chemotherapy, Adjuvant
Female
Humans
Middle Aged
Neoplasm Recurrence, Local
Premenopause
Receptors, Estrogen
Receptors, Progesterone
Retrospective Studies

authors with profiles

Frederick Howard
Sudha Yarlagadda
Rita Nanda
Sarah Shubeck
Dezheng Huo